{"url_path":"/sec/autl/8-k/2026-08-11/item-7-01","section_key":"item-7-01","section_title":"Item 7.01 Regulation FD Disclosure.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-08-11","source_url":"https://www.sec.gov/Archives/edgar/data/1730463/0001730463-26-000119-index.html","accession_number":"0001730463-26-000119","cik":"0001730463","ticker":"AUTL","issuer_name":"Autolus Therapeutics plc","edgar_url":"https://www.sec.gov/Archives/edgar/data/1730463/0001730463-26-000119-index.html","primary_entity_key":"0001730463","primary_entity_name":"Autolus Therapeutics plc"},"word_count":151,"has_tables":true,"body_markdown":"Item 7.01 Regulation FD Disclosure.\n\nIn connection with its conference call on August 11, 2026 to discuss its results for the quarter ended June 30, 2026, the Company will utilize an updated corporate presentation, a copy of which is furnished as Exhibit 99.2 to this Current Report on Form 8-K and incorporated herein by reference.\n\nThe information in this Item 7.01, including Exhibit 99.2 attached hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section. The information contained herein and in the accompanying exhibit is not incorporated by reference in any filing of the Company under the Securities Act or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific reference in such filing."}